<?xml version='1.0' encoding='utf-8'?>
<document id="28069721"><sentence text="Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport."><entity charOffset="43-56" id="DDI-PubMed.28069721.s1.e0" text="Lobeglitazone" /><entity charOffset="73-85" id="DDI-PubMed.28069721.s1.e1" text="Atorvastatin" /><pair ddi="false" e1="DDI-PubMed.28069721.s1.e0" e2="DDI-PubMed.28069721.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28069721.s1.e0" e2="DDI-PubMed.28069721.s1.e1" /></sentence><sentence text="Cytochrome P450 enzymes and human organic anion transporting polypeptide (OATP) 1B1 are reported to be involved in the pharmacokinetics of lobeglitazone (LB), a new peroxisome proliferator-activated receptor γ agonist"><entity charOffset="139-152" id="DDI-PubMed.28069721.s2.e0" text="lobeglitazone" /></sentence><sentence text=" Atorvastatin (ATV), a substrate for CYP3A and human OATP1B1, is likely to be coadministered with LB in patients with the metabolic syndrome"><entity charOffset="1-13" id="DDI-PubMed.28069721.s3.e0" text="Atorvastatin" /><entity charOffset="15-18" id="DDI-PubMed.28069721.s3.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.28069721.s3.e0" e2="DDI-PubMed.28069721.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28069721.s3.e0" e2="DDI-PubMed.28069721.s3.e1" /></sentence><sentence text=" We report herein on a study of potential interactions between LB and ATV in rats"><entity charOffset="70-72" id="DDI-PubMed.28069721.s4.e0" text="ATV" /></sentence><sentence text=" When LB was administered intravenously with ATV, the systemic clearance and volume of distribution at steady state for LB remained unchanged (2"><entity charOffset="45-47" id="DDI-PubMed.28069721.s5.e0" text="ATV" /></sentence><sentence text="67 ± 0" /><sentence text="63 ml/min per kg and 289 ± 20 ml/kg, respectively), compared with that of LB without ATV (2"><entity charOffset="85-87" id="DDI-PubMed.28069721.s7.e0" text="ATV" /></sentence><sentence text="34 ± 0" /><sentence text="37 ml/min per kg and 271 ± 20 ml/kg, respectively)" /><sentence text=" Although the tissue-to-plasma partition coefficient (Kp) of LB was not affected by ATV in most major tissues, the liver Kp for LB was decreased by ATV coadministration"><entity charOffset="84-86" id="DDI-PubMed.28069721.s10.e0" text="ATV" /><entity charOffset="148-150" id="DDI-PubMed.28069721.s10.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.28069721.s10.e0" e2="DDI-PubMed.28069721.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28069721.s10.e0" e2="DDI-PubMed.28069721.s10.e1" /></sentence><sentence text=" Steady-state liver Kp values for three levels of LB were significantly decreased as a result of ATV coadministration"><entity charOffset="97-99" id="DDI-PubMed.28069721.s11.e0" text="ATV" /></sentence><sentence text=" LB uptake was inhibited by ATV in rat OATP1B2-overexpressing Madin-Darby canine kidney cells and in isolated rat hepatocytes in vitro"><entity charOffset="28-30" id="DDI-PubMed.28069721.s12.e0" text="ATV" /></sentence><sentence text=" After incorporating the kinetic parameters for the in vitro studies into a physiologically based pharmacokinetics model, the characteristics of LB distribution to the liver were consistent with the findings of the in vivo study" /><sentence text=" It thus appears that the distribution of LB to the liver is mediated by the hepatic uptake of transporters such as rat OATP1B2, and carrier-mediated transport is involved in the liver-specific drug-drug interaction between LB and ATV in vivo"><entity charOffset="231-233" id="DDI-PubMed.28069721.s14.e0" text="ATV" /></sentence><sentence text="" /></document>